Quanta Inc (fka QNTA)

[JediMozart]

QNTA long / bullish… imo lots to be excited about with this stock … $$$
Great positive escozine data :
{“Physicians observed that patients who originally had strong adverse reactions
to COVID-19 vaccines and who were given Escozine®, experienced significantly
lessened side effects. Typical vaccine side effects are similar to symptoms of
the actual COVID-19 virus, including body cough, aches, fatigue and fever,
among others.

These observations have led the Company to move forward with pursuing an
additional pilot study on the drug, looking to prove its effectiveness in
decreasing side effects of vaccinations for COVID-19. Management plans to meet
with the Ministry of Health and the office of the President of the DR to
present the observations and seek further guidance on next steps for approval
as a complimentary product for vaccine recipients.

“It only makes sense that Escozine® would be effective in mitigating side
effects of COVID-19 vaccines as it has been proven to be effective in treating
or diminishing the symptoms of the COVID-19 virus itself,” said Medolife CEO
Dr. Arthur Mikaelian. “Specifically in the DR, and in many places around the
world, vaccine hesitancy is becoming more common for a multitude of reasons,
including the side effects associated with them. While the idea of pursuing
Escozine® as a complementary product to COVID-19 vaccines was not originally
included in our study parameters, we plan to quickly initiate a pilot study in
order to prove its potential effectiveness as such. If we are able to do so,
Escozine® could have global applications as a complementary medicine,
decreasing the severity of side effects of COVID-19 vaccines, and hopefully,
decreasing vaccine hesitancy in patients with a high side effect risk rate.”

The Company is currently pursuing approval of Escozine® as both a palliative
and therapeutic treatment for the virus in the US and the DR, with positive
data from preclinical studies suggesting its effectiveness. Given that
Escozine® has received product registration as a natural alternative medicine
in Dominican and been a part of these clinical studies, physicians at the
clinic provided doses to certain vaccine recipients and observed this
reduction in side effects.

Escozine®, which is comprised of scorpion peptides that have been polarized by
the Company’s proprietary process, is Medolife’s lead drug candidate. The
Company recently announced that it has received a detailed response from the
US Food and Drug Administration (FDA) on its Pre-Investigational New Drug
(Pre-IND) submission on Escozine® as both a potential palliative and
therapeutic drug for the COVID-19 virus. In the response, the FDA acknowledged
the Company’s clinical trial that took place in the DR as a proof-of-concept
study and provided detailed guidelines for next steps in its approval process.
The Company is in the process of outlining an additional DNA toxicology study
as well as a formal clinical Pharmacokinetic (PK) study that it hopes to
launch in short order.”}

https://www.bloomberg.com/press-releases/2021-07-08/quanta-inc-medolife-rx-clinical-observations-demonstrates-effectiveness-of-escozine-in-complementary-use-with-covid-19”}